Key Insights

Highlights

Success Rate

90% trial completion (above average)

Published Results

13 trials with published results (10%)

Research Maturity

74 completed trials (59% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

6.4%

8 terminated out of 125 trials

Success Rate

90.2%

+3.7% vs benchmark

Late-Stage Pipeline

17%

21 trials in Phase 3/4

Results Transparency

18%

13 of 74 completed with results

Key Signals

13 with results90% success

Data Visualizations

Phase Distribution

80Total
Not Applicable (33)
Early P 1 (1)
P 1 (7)
P 2 (18)
P 3 (11)
P 4 (10)

Trial Status

Completed74
Unknown24
Recruiting11
Terminated8
Withdrawn4
Active Not Recruiting3

Trial Success Rate

90.2%

Benchmark: 86.5%

Based on 74 completed trials

Clinical Trials (125)

Showing 20 of 20 trials
NCT03083431Phase 2RecruitingPrimary

Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity

NCT05387941Phase 1CompletedPrimary

Pharmacokinetics and Safety of Dexamethasone Eye Drops in Preterm Infants

NCT06315556RecruitingPrimary

An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)

NCT05705258RecruitingPrimary

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

NCT04515524Active Not RecruitingPrimary

Extension Study to Evaluate the Long-Term Outcomes of Pediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe-ROP-1920 Study (Acronym: Butterfleye Next)

NCT04634578Phase 2Active Not RecruitingPrimary

Bevacizumab Treatment For Type 1 ROP

NCT02820662Not ApplicableCompletedPrimary

Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants

NCT06517836Not ApplicableCompletedPrimary

Automated Screening Device to Detect MTMROP

NCT06109285Not ApplicableActive Not RecruitingPrimary

Validation of i-ROP DL to Detect More Than Mild ROP

NCT05133999CompletedPrimary

Iron and Retinopathy of Prematurity (ROP)

NCT05558059RecruitingPrimary

Imaging Retinal Vasculature in Infant Eyes

NCT04995341Not ApplicableRecruitingPrimary

Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

NCT05304949CompletedPrimary

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

NCT07016984Not ApplicableCompleted

Comfort Level in Premature Infants Undergoing Retinopathy of Prematurity Screening

NCT05576792CompletedPrimary

A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

NCT05043077Phase 4CompletedPrimary

Efficacy and Safety of Mydriatic Microdrops for Retinopathy Of Prematurity Screening

NCT05100212Phase 2CompletedPrimary

umBilical Or Adult Donor Red Blood Cells in Extremely Low Gestational Age Neonates and Retinopathy of Prematurity (BORN)

NCT06067958Phase 3RecruitingPrimary

Intranasal Dexmedetomidine for Pain Management During Screening for Retinopathy of Prematurity

NCT05152862CompletedPrimary

Improve Screening Criteria for Retinopathy of Prematurity in Two French Center

NCT06672913Not ApplicableRecruiting

Impact of Standardized Skin-to-Skin Care on Clinical Outcomes in Infants Born ≤ 32 Weeks: A Multicenter Study

Scroll to load more

Research Network

Activity Timeline